Narula, Gaurav https://orcid.org/0000-0002-8539-295X
Keerthivasagam, Swaminathan https://orcid.org/0000-0003-2834-3868
Jain, Hasmukh
Punatar, Sachin https://orcid.org/0000-0002-7461-4772
Chichra, Akanksha
Dhamne, Chetan
Tembhare, Prashant https://orcid.org/0000-0002-9030-0415
Subramanian, Papagudi Ganesan https://orcid.org/0000-0001-9107-5937
Patkar, Nikhil https://orcid.org/0000-0001-9234-2857
Poojary, Minal
Gokarn, Anant
Mirgh, Sumeet https://orcid.org/0000-0003-0642-2207
Jindal, Nishant
Nisar, Albeena
Pandit, Deepali
Pandit, Khushali
Dwivedi, Alka
Karulkar, Atharva
Jaiswal, Ankesh Kumar
Khan, Aalia
Shah, Shreshtha
Rafiq, Afrin https://orcid.org/0000-0002-2336-7070
Basu, Moumita
Pendhari, Juber
Asija, Sweety
Chowdury, Ambalika
Banik, Ankit
Moulik, Nirmalya Roy
Srinivasan, Shyam
Bhosle, Shilpushp
Hiregoudar, Sumathi
Ojha, Shashank
Nayak, Lingaraj
Thorat, Jayshree
Bagal, Bhausaheb https://orcid.org/0000-0001-9754-0182
Sengar, Manju https://orcid.org/0000-0002-3509-5682
Khattry, Navin https://orcid.org/0000-0001-5708-6472
Banavali, Shripad
Highfill, Steven
Shah, Nirali N. https://orcid.org/0000-0002-8474-9080
Purwar, Rahul https://orcid.org/0000-0003-3319-0309
Article History
Received: 17 December 2024
Revised: 24 March 2025
Accepted: 2 April 2025
First Online: 24 April 2025
Change Date: 15 May 2025
Change Type: Update
Change Details: The original online version of this article was revised: In the legend of fig. 3 the colors representing CR and PR have been interchanged. In the Figure, the Green bars correctly represent CR, and the blue bars correctly represent PR. However, in the Legend, the Box against CR has the blue color, and the box adjacent to PR has Green color. The correction needed is to change the colors of these boxes so that the box next to CR shows the Green color and the box next to PR shows the blue color.
Change Date: 20 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-025-01308-7
Competing interests
: GN serves as a scientific advisor/board member in ImmunoACT. HJ has received research and/or clinical trial support from ImmunoACT, Zydus, and Intas Pharmaceuticals. RP, AK, SS, and AF are equity holders in a private company, have memberships on the entity’s Board of Directors or advisory committees, hold patents and royalties with ImmunoACT, and are currently employed there. JT serves as a consultant for ImmunoACT. NNS is a consultant and/or advisory board member for ImmunoACT, VOR, Cargo, and Lentigen. The remaining authors declare no conflict of interest.
: The prospective study was approved by the institutional review boards and ethical committee clearance was obtained (ECR/149/Inst/MH/2023 and IITB-IEC/2018/023).
: Informed consent was obtained from the caretakers of the patients in our study.